Rigel said Vepenew, acquired in June and launched in mid-August, generated 6.6 million in sales in its first six weeks. Net product sales of 72 million in the past quarter were the company's largest quarterly figure ever. The company plans to present updated R289 data at the ASH meeting in December and start a registrational study in 2027 with FDA concurrence.
RIGL · Rigel Pharmaceuticals Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Rigel generated $72.3 million in net product sales for the third quarter of 2026, up 13% year-over-year, including $6.6 million from Vepenu.
Rigel reported third-quarter total revenues of $80.9 million and net income of $13.2 million, while VEPPANU generated $6.6 million in initial net product sales. It updated the 2026 revenue outlook to approximately $290 to $295 million, excluding VEPPANU.
VEPPANU generated $6.6 million in initial net product sales from its August 13, 2026 launch through September 30, 2026, while nine-month TAVALISSE sales rose 15% to $130.6 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Rigel reported Q2 net product sales of $67.0 million (+14% YoY) and net income of $17.3 million, in-licensed and is preparing the mid-August U.S. launch of VEPPANU, and raised its 2026 total revenue guidance to $285–$295 million while reiterating an expected full-year profit.
- + Net product sales rose 14% YoY to $67.0 million in Q2 2026.
- + TAVALISSE net product sales grew 18% YoY to $47.4 million.
- + REZLIDHIA net product sales grew 27% YoY to $8.9 million.
- + Rigel raised 2026 total revenue guidance to approximately $285–$295 million from the prior $275–$290 million range.
- + VEPPANU in-license expands commercial portfolio, with U.S. commercial availability expected in mid-August.
- + Company continues to anticipate positive full-year 2026 net income while funding new and existing programs.
- − Q2 net income fell to $17.3 million from $59.6 million a year ago, due largely to a prior-year $40.0M Lilly collaboration release.
- − GAVRETO net product sales declined 10% YoY to $10.7 million.
- − Total costs and expenses rose 36% YoY to $55.1 million, driven by higher personnel, R&D, and Arvinas/Pfizer-license costs.
- − Cash, cash equivalents and short-term investments fell to $95.3 million at June 30, 2026 from $155.0 million at December 31, 2025, partly reflecting a $70.0 million upfront payment to Arvinas and Pfizer.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cencora, Inc. | 21% | the three months ended June 30, 2026 filing | — |
| GAVRETO net product sales | $20.3M | the six months ended June 30, 2026 | — |
| McKesson Corporation | 46% | the three months ended June 30, 2026 filing | — |
| REZLIDHIA net product sales | $17M | the six months ended June 30, 2026 | — |
| TAVALISSE net product sales | $84.7M | the six months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RIGL
this stock
Rigel Pharmaceuticals Inc
|
$800.84M | -0.7% | +64.1% | 2.6 | 13.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 20
Rigel said Vepenew, acquired in June and launched in mid-August, generated 6.6 million in sales in its first six weeks. Net product sales of 72 million in the past quarter were the company's largest quarterly figure ever. The company plans to present updated R289 data at the ASH meeting in December and start a registrational study in 2027 with FDA concurrence.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RIGL | -4.5% | -13.0% | +39.5% | -17.1% | -0.7% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -0.6% | -7.4% | +43.0% | -13.7% | -7.8% |